Casandra
Casandra Test Code QD11401Version 1 (DRAFT)
Performing Lab
Lab Quest DiagnosticsLab Test ID N/A
Ki‑67 IHC pharmDx (Abemaciclib) with Interpretation
Clinical Use
Order TestUse
Ki‑67 (MIB‑1) is a proliferation marker used to identify patients with hormone receptor‑positive (HR+), HER2‑negative early breast cancer at high risk of recurrence who may benefit from adjuvant therapy with abemaciclib (Verzenio®) in combination with endocrine therapy, when Ki‑67 score is ≥20%, as determined by an FDA‑approved companion diagnostic test.
Special Instructions
Not provided.
Limitations
Not provided.
Test Details
FDA Approved
Methodology
Immunoassay (IHC)
Biomarkers
Ki‑67 (MIB‑1)
ProteinIHC
Expression • Quantitative (Continuous) (e.g., copies/mL, % expression)
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen Requirements
Not provided.
Similar Tests
Other tests from different labs that may be relevant
Ki-67(MIB-1), Breast, Quantitative Immunohistochemistry, Automated
Mayo Clinic Lab
Ki-67(MIB-1), Breast, Semi-Quantitative Immunohistochemistry, Manual
Mayo Clinic Lab
Ki-67, MIB-1, by Immunohistochemistry
ARUP Laboratories
Ki-67 with Interpretation by Immunohistochemistry
ARUP Laboratories
Ki‑67
NeoGenomics
Ki67
MPLN
Ki-67 (MIB-1) Immunostain, Technical Component Only
Mayo Clinic Lab
Ki67, technical only
MPLN
Proliferation Marker Ki67, Paraffin Block
Labcorp
Ki67 NET
NeoGenomics